Tag: NBE-Therapeutics
SOTIO and LegoChem Biosciences Sign Exclusive Collaboration and License Agreement
Clinical stage immuno-oncology company SOTIO Biotech and LegoChem Biosciences (LCB), a biotechnology company focused on developing its clinical-stage platform technology to develop antibody-drug conjugates...
NBE-Therapeutics and Exelixis Sign Agreement to Advance Best-in-class ADCs Against Multiple...
Privately-owned Swiss biotech NBE-Therapeutics and Exelixis, confirmed a new partnership to discover and develop multiple antibody-drug conjugates (ADCs) for applications within oncology and hematology....
Boehringer Ingelheim Venture Fund and PPF Group Close a US $...
Privately-owned Swiss biotech company NBE-Therapeutics confirmed closing of a US $ 22M Series C financing round. The financing round was led by its existing...
Steffen Heeger, MD, Ph.D to Lead NBE-Therapeutics’ Clinical iADC Development
Privately-owned Swiss, Basel-based, NBE-Therapeutics has appointed Steffen Heeger MD, Ph.D. as Chief Medical Officer to lead the clinical development of NBE-002, the company's first...
WuXi Biologics and NBE-Therapeutics Collaborate in Development and Manufacturing Partnership
WuXi Biologics, an open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and Swiss biotech NBE-Therapeutics, developing best-in-class, next-generation...
NBE Therapeutics Receives Additional Series B Financing – Supports Clinical Testing...
Novo Holdings, a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, manages the Foundation's investment assets. Earlier this year, the...
PepTalk 2017: Antibody-drug Conjugates and the Promise of Innovation
ADC or antibody-drug conjugates have recently been at the forefront of cancer research, and according to the experts presenting their latest data during the...
NBE Therapeutics and SOTIO Collaborate in the Development of the Next-Gen...
NBE Therapeutics, a privately owned Swiss, Basel-based Biotech company, and SOTIO, a biotechnology company located in Prague, Czech Republic, with facilities in Europe, the United...
London Calling: The Cutting-edge of Novel ADC Technologies
Major players in the rapidly advancing field of antibody drug conjugates (ADCs) will meet in London, United Kingdom, on 23-24 May for the annual...
